Sue Rankin
Nurse Practitioner · Amarillo, TXNPI 1891950721
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,260 of the $88,722 with a category attached, or 97.2%. Insulet Corporation accounts for 72.0% of it on its own, with 19 other manufacturers making up the rest. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $482.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$64K
- Medtronic$24K
- Abbott$154
- Sanofi-aventis U.S. LLC$107
- Tandem Diabetes Care, Inc.$59
- Rhythm Pharmaceuticals, Inc.$55
- plus $393 from 14 others
What the payments were for
- Speaking & faculty fees$86,26097%
- Travel & lodging$1,0171%
- Food & beverage$1,4452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 97 | $63,870 |
| Medtronic | 58 | $24,085 |
| Abbott | 2 | $154 |
| Sanofi-aventis U.S. LLC | 2 | $107 |
| Tandem Diabetes Care, Inc. | 4 | $59 |
| Rhythm Pharmaceuticals, Inc. | 2 | $55 |
| Xeris Pharmaceuticals, Inc. | 3 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Sequel Med Tech, LLC | 1 | $38 |
| Biomarin Pharmaceutical Inc. | 2 | $35 |
| Soleno Therapeutics, Inc. | 1 | $34 |
| AbbVie | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Novo Nordisk | 1 | $25 |
| Eton Pharmaceuticals, Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| BETA Bionics, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$63,410
- MINIMED 780G$16,663
- MINIMED 770G$4,450
- Minimed 770G System$2,300
- FREESTYLE LIBRE 3$138
How this compares
$88,722 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $25,890 |
| HumalogInsulin Lispro | 11 | $4,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCHumalog | $11 | $4,30511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Amarillo
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Onna FeuchterSouthlake$108K
- Stephanie AgrellaRound Rock$102K
- Adrian FelderPlano$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.